Johnson & Johnson’s JNJ pharmaceutical company, Janssen announced that it has submitted a supplemental biologics license application (sBLA) for inflammatory drug, Stelara, to the FDA. The sBLA is ...
Please provide your email address to receive an email when new articles are posted on . Imuldosa, an ustekinumab biosimilar, is approved for multiple inflammatory diseases, including Crohn’s disease ...
REYKJAVIK, Iceland--(BUSINESS WIRE)--Alvotech Holdings S.A. (“Alvotech”), a global biotech company focused solely on the development and manufacture of biosimilar medicines for patients worldwide, ...
Imuldosa, a Stelara biosimilar, is approved for autoimmune diseases, marking the fifth ustekinumab biosimilar in the US market. Stelara, a top-grossing biologic, underwent CMS price negotiations with ...
Amgen AMGN has announced positive preliminary data from a phase III study on ABP 654, its biosimilar candidate, to J&J’s JNJ blockbuster drug Stelara (ustekinumab) in plaque psoriasis indication. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback